HIGHLIGHTS
- who: Analía Azaro from the Department of Medical Oncology, Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy University of Cambridge, Cambridge, UK have published the Article: A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function, in the Journal: (JOURNAL)
- what: This study assessed the PK and safety of cabazitaxel in patients with advanced solid tumors and moderate or severe renal impairment compared with normal renal function. From a sensitivity analysis, where CrCL changes during the time course of the study were taken into . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.